Abstract
Casein Kinase I η (CKI) and Casein Kinase I δ (CKIδ) are Serine/Threonine Kinases that have been implicated in several human conditions and have been receiving increasing attention as potential therapeutic targets. Recent findings in gastrointestinal cancers strengthen this notion and suggest that they may also play important roles in both colon cancer and pancreatic cancer, which are among the most common and deadly cancers affecting both men and women. In this short review, we summarize up to date what is known about these two kinases and their involvement in carcinogenesis and other pathological conditions. Our emphasis is on their implications in gastrointestinal cancers and their potential for screening and cancer therapy.
Keywords: CKIη, CKIδ, colon cancer, pancreatic cancer, biomarkers, IC261
Current Cancer Therapy Reviews
Title: Roles of Casein Kinase I η and δ in Gastrointestinal Cancers: Potential New Screening Markers and Drug Targets
Volume: 5 Issue: 3
Author(s): Cristina Modak and Jianyuan Chai
Affiliation:
Keywords: CKIη, CKIδ, colon cancer, pancreatic cancer, biomarkers, IC261
Abstract: Casein Kinase I η (CKI) and Casein Kinase I δ (CKIδ) are Serine/Threonine Kinases that have been implicated in several human conditions and have been receiving increasing attention as potential therapeutic targets. Recent findings in gastrointestinal cancers strengthen this notion and suggest that they may also play important roles in both colon cancer and pancreatic cancer, which are among the most common and deadly cancers affecting both men and women. In this short review, we summarize up to date what is known about these two kinases and their involvement in carcinogenesis and other pathological conditions. Our emphasis is on their implications in gastrointestinal cancers and their potential for screening and cancer therapy.
Export Options
About this article
Cite this article as:
Modak Cristina and Chai Jianyuan, Roles of Casein Kinase I η and δ in Gastrointestinal Cancers: Potential New Screening Markers and Drug Targets, Current Cancer Therapy Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339409788982214
DOI https://dx.doi.org/10.2174/157339409788982214 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets The Effects of Insulin and Insulin-Like Growth Factors on Tumor Vascularization: New Insights of Insulin-Like Growth Factor Family in Cancer
Current Medicinal Chemistry Regulation of miRNA Processing and miRNA Mediated Gene Repression in Cancer
MicroRNA Evolution of Resistance to Cancer Therapy
Current Pharmaceutical Design Cytokines and Chemokines as Regulators of Angiogenesis in Health and Disease
Current Pharmaceutical Design The Hormetic Role of Dietary Antioxidants in Free Radical-Related Diseases
Current Pharmaceutical Design Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter
Current Drug Metabolism The Use of Cyclodextrins Nanoparticles for Oral Delivery
Current Medicinal Chemistry The Immune Protective Effect of the Mediterranean Diet against Chronic Low-grade Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The Antidepressant-like Effects of Estrogen-mediated Ghrelin
Current Neuropharmacology Long Non-Coding RNA: An Emerging Paradigm of Pancreatic Cancer
Current Molecular Medicine Therapeutic Agents Against COVID-19 with Clinical Evidence
Current Pharmaceutical Design Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
Current Cancer Drug Targets Multifunctional Delivery Systems for Advanced oral Uptake of Peptide/Protein Drugs
Current Pharmaceutical Design Synthesis and Preliminary Biological Evaluation of Chrysin Derivatives as Potential Anticancer Drugs
Medicinal Chemistry Improved Drug Delivery System for Cancer Treatment by D-Glucose Conjugation with Eugenol From Natural Product
Current Drug Delivery Th1-mediated Pathology in Mouse Models of Human Disease is Ameliorated by Concurrent Th2 Responses to Parasite Antigens
Current Topics in Medicinal Chemistry Defining the Role of Integrin αvβ6 in Cancer
Current Drug Targets Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants
Current Topics in Medicinal Chemistry Eurycoma longifolia, A Potential Phytomedicine for the Treatment of Cancer: Evidence of p53-mediated Apoptosis in Cancerous Cells
Current Drug Targets